西波尼莫德对二次渐进性多发性硬化症的临床和放射学参数的影响:现实世界的前性研究
Konstantina Stavrogianni1,2, Dimitrios K Kitsos1, Vasileios Giannopapas1,3,4
1Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Journal of clinical neurology (Seoul, Korea)
|November 6, 2024
概括
在12个月的时间里,西波尼莫德有效地减少了继发性进展性多发性硬化症 (SPMS) 患者的复发,MRI病变,疲劳和尿道问题,保持了残疾稳定性.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 二次渐进性多发性硬化症 (SPMS) 是一种具有有限治疗选择的衰弱性神经系统疾病.
- 西波尼莫德是一种口服的基-1-酸盐受体调节剂,研究了活性SPMS.
- 了解siponimod在现实临床环境中的疗效至关重要.
研究的目的:
- 为了评估siponimod在活跃SPMS患者的12个月治疗效果.
- 评估西波尼莫德对临床和放射性疾病标志物的影响.
- 分析严重残疾患者 (EDSS ≥5.0) 的治疗效应.
主要方法:
- 一个单一中心的纵向研究包括50名活跃的SPMS患者,他们接受了siponimod治疗.
- 临床评估包括年度复发率 (ARR),扩展残疾状态量表 (EDSS) 和符号数字模式测试.
- 监测了放射性标志物 (加多增强的病变 - GdE+) 和患者报告的结果 (修改疲劳影响量表 - MFIS,空白后残留 - PVR体积).
主要成果:
- 西波尼莫德显著降低了ARR,GdE+病变和MFIS得分 (p<0.001).
- 身体和认知障碍的进展保持稳定 (p>0.05).
- 观察到PVR体积显著下降 (p<0.001),在EDSS≥5.0.0的子组中一致.
结论:
- 西波尼莫德在12个月的时间内在管理活跃的SPMS方面表现出显著的有效性.
- 治疗减少了疾病活动的关键标志物,改善了疲劳.
- 在SPMS患者中,西波尼莫德保持了残疾稳定性,并对尿功能产生了积极影响.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...


